Related Experiment Video

Updated: Aug 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Multidrug resistance in non-small-cell lung cancer

G V Scagliotti1, S Novello, G Selvaggi

  • 1University of Turin, Department of Clinical & Biological Sciences, Azienda Ospedaliera S. Luigi-Orbassano, Torino, Italy. scagliotti@ihnet.it

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|December 3, 1999
PubMed

Insights

Multidrug resistance (MDR) in lung cancer involves complex cellular mechanisms and tumor characteristics, leading to treatment failure. Understanding these resistance types is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Cytotoxic drug resistance is a primary driver of treatment failure in cancer therapy.
  • Multidrug resistance (MDR) phenotypes arise from complex interactions between tumor characteristics and cellular mechanisms.
  • In lung cancer, MDR is a significant challenge, impacting treatment efficacy.

Purpose of the Study:

  • To elucidate the complex mechanisms underlying multidrug resistance in lung cancer.
  • To define the different types of MDR observed in lung cancer based on cellular drug targets.
  • To explore the role and interplay of various MDR forms in lung cancer treatment.

Main Methods:

  • Characterization of tumor-specific factors influencing drug resistance, including cellular characteristics and vascularization.
  • Identification and classification of distinct multidrug resistance phenotypes in lung cancer.
  • Analysis of cellular drug targets associated with different MDR mechanisms, such as P-glycoprotein, MRP, topoisomerases II, and lung resistance-related protein.

Main Results:

  • Four distinct types of multidrug resistance have been identified in lung cancer.
  • These types are differentiated by their specific cellular drug targets: classical MDR, non-P-glycoprotein MDR (MRP), atypical MDR (via topoisomerases II), and lung resistance-related protein.
  • The precise contribution of each MDR type to overall treatment failure in lung cancer remains incompletely understood.

Conclusions:

  • Multidrug resistance in lung cancer is multifaceted, involving various cellular mechanisms and drug targets.
  • The identified MDR types highlight the complexity of resistance pathways.
  • Further research is necessary to fully comprehend the role of these MDR forms and to develop targeted therapeutic strategies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...